Clinical Trials | June 09, 2026
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
